Search
forLearn
5 / 801 resultslearn nicotinamide
learn Clascoterone
a novel topical treatment that inhibits DHT on androgen receptors
learn KY19382
compound that activates Wnt/β-catenin to promote hair regrowth and create new hair follicles
learn Tricopper peptides
Research
5 / 1000+ resultsresearch Novel anti-aging gene NM_026333 contributes to proton-induced aging via NCX1-pathway
The gene NM_026333 slows down aging by affecting the NCX1 pathway and could be targeted for anti-aging treatments.
research Vitamin D and Human Health: Lessons from Vitamin D Receptor Null Mice
Mice without the vitamin D receptor have bone issues and other health problems, suggesting vitamin D is important for preventing various diseases in humans.
research Hormonal Control of Cardiac Action Potential Phase 1 Currents in the Brugada Syndrome
Androgens may increase arrhythmias in Brugada Syndrome, while Finasteride could reduce them.
research Emerging Roles for Ion Channels in Ovarian Cancer: Pathomechanisms and Pharmacological Treatment
Ion channels play a key role in ovarian cancer growth and treatment resistance.
research Targeting cardiac hypertrophy through a nuclear co‐repressor
Targeting NCoR1 can help treat heart enlargement and dysfunction.
Community Join
5 / 1000+ resultscommunity Kintor KX -826 Pyrilutamide Adds 1 Year Phase 3 Trial For Safety
KX-826/pyrilutamide is undergoing an additional one-year safety and efficacy trial in China after a six-month study. Some participants speculate on the reasons for the extended trial and discuss the potential of other treatments.
community Anageninc no longer sell KX-826 (Pyrilutamide) due to receiving a cease and desist letter from Kintor :(
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Anageninc stopped selling KX-826 (Pyrilutamide) due to a cease and desist letter from Kintor, but this may indicate promising study results and a potential 2024 release.
community FCE 28260: A Forgotten 5α-Reductase Inhibitor
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.
community KX-826 Pyrilutamide1% coming soon
KX-826 Pyrilutamide 1% is launching soon, and users are discussing its potential benefits and drawbacks compared to other treatments like Minoxidil and finasteride. Some users are skeptical about its effectiveness, while others are hopeful it will be a safer alternative.
community REVOLUTION in AUGUST: New possibilities according to Dr. Muñoz (pinacidil, cromakalim, diazoxide and nicorandil)
Dr. Muñoz's discovery suggests that targeting potassium channels in fibroblasts could reactivate hair growth, offering new treatment possibilities for alopecia. Potential strategies include using minoxidil, diazoxide, and other potassium channel openers, as well as bioelectric devices and direct growth factor applications.